Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $15.8 million.

  • Protalix BioTherapeutics' Non-Current Assets rose 1496.72% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.5 million, marking a year-over-year decrease of 233.43%. This contributed to the annual value of $13.3 million for FY2024, which is 801.96% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Non-Current Assets is $15.8 million, which was up 1496.72% from $13.0 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Non-Current Assets peaked at $15.8 million during Q3 2025, and registered a low of $10.9 million during Q4 2022.
  • For the 5-year period, Protalix BioTherapeutics' Non-Current Assets averaged around $13.0 million, with its median value being $13.0 million (2025).
  • Per our database at Business Quant, Protalix BioTherapeutics' Non-Current Assets plummeted by 5183.4% in 2021 and then surged by 3655.13% in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Non-Current Assets (Quarter) stood at $12.0 million in 2021, then dropped by 9.1% to $10.9 million in 2022, then soared by 32.96% to $14.5 million in 2023, then dropped by 8.02% to $13.3 million in 2024, then grew by 18.16% to $15.8 million in 2025.
  • Its Non-Current Assets was $15.8 million in Q3 2025, compared to $13.0 million in Q2 2025 and $13.4 million in Q1 2025.